Ichiro Koyama1, Hisashi Bashuda2, Koichiro Uchida2, Ken-Ichiro Seino3, Sonoko Habu2, Ichiro Nakajima1, Shohei Fuchinoue1, Ko Okumura2, Satoshi Teraoka4. 1. Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 2. Atopy Research Center, Juntendo University Hospital, Juntendo University School of Medicine, Tokyo, Japan. 3. Division of immunobiology, Institute for genetic medicine, Hokkaido University, Sapporo, Japan. 4. Department of Transplant Surgery, Mita Hospital, International University of Health and Welfare, Tokyo, Japan.
Abstract
BACKGROUND: Although the outcome of kidney transplantation (KTx) has improved, various adverse effects of immunosuppressants and chronic rejection aggravate the long-term prognosis of patients. Therefore, the induction of immune tolerance may be an effective therapeutic strategy. METHODS: A clinical trial aiming at immune tolerance induction was conducted in kidney transplant recipients from HLA mismatched living donors by infusing autologous donor-specific regulatory T cells (Treg). To obtain Treg, recipient's peripheral blood mononuclear cells were cocultured with irradiated donor cells in the presence of anti-CD80/CD86 monoclonal antibody for 2 weeks. For preconditioning, splenectomy + cyclophosphamide (CP) was employed in the first series (group A; n = 9). In group B, splenectomy was substituted by preadministration of rituximab (group B; n = 3). In the latest cases, rituximab + rabbit antithymocyte globulin was administered instead of cyclophosphamide (group C; n = 4). Twelve days after KTx, the cultured cells were intravenously infused, and immunosuppressants were gradually tapered thereafter. RESULTS: Although mixed lymphocyte reaction was remarkably suppressed in a donor-specific fashion, 6 out of 9 patients from group A, 1 out of 3 from group B, and 1 out of 4 from group C developed acute rejection within 1 year after KTx. Complete cessation of immunosuppression was not achieved, and a small dose of immunosuppressants was continued. CONCLUSIONS: The adoptive transfer of autologous ex vivo-expanded Treg is 1 of the options to possibly induce alloimmune hyporesponsiveness. However, in the present study, further regimen optimization is still required and should be the focus of future investigations.
BACKGROUND: Although the outcome of kidney transplantation (KTx) has improved, various adverse effects of immunosuppressants and chronic rejection aggravate the long-term prognosis of patients. Therefore, the induction of immune tolerance may be an effective therapeutic strategy. METHODS: A clinical trial aiming at immune tolerance induction was conducted in kidney transplant recipients from HLA mismatched living donors by infusing autologous donor-specific regulatory T cells (Treg). To obtain Treg, recipient's peripheral blood mononuclear cells were cocultured with irradiated donor cells in the presence of anti-CD80/CD86 monoclonal antibody for 2 weeks. For preconditioning, splenectomy + cyclophosphamide (CP) was employed in the first series (group A; n = 9). In group B, splenectomy was substituted by preadministration of rituximab (group B; n = 3). In the latest cases, rituximab + rabbit antithymocyte globulin was administered instead of cyclophosphamide (group C; n = 4). Twelve days after KTx, the cultured cells were intravenously infused, and immunosuppressants were gradually tapered thereafter. RESULTS: Although mixed lymphocyte reaction was remarkably suppressed in a donor-specific fashion, 6 out of 9 patients from group A, 1 out of 3 from group B, and 1 out of 4 from group C developed acute rejection within 1 year after KTx. Complete cessation of immunosuppression was not achieved, and a small dose of immunosuppressants was continued. CONCLUSIONS: The adoptive transfer of autologous ex vivo-expanded Treg is 1 of the options to possibly induce alloimmune hyporesponsiveness. However, in the present study, further regimen optimization is still required and should be the focus of future investigations.
Authors: Mohamed B Ezzelarab; Hong Zhang; Kazuki Sasaki; Lien Lu; Alan F Zahorchak; Dirk J van der Windt; Helong Dai; Angelica Perez-Gutierrez; Jay K Bhama; Angus W Thomson Journal: Transplantation Date: 2021-09-01 Impact factor: 5.385
Authors: Rainer Oberbauer; Matthias Edinger; Gabriela Berlakovich; Peter Kalhs; Nina Worel; Georg Heinze; Michael Wolzt; Thomas Lion; Thomas Wekerle Journal: Front Med (Lausanne) Date: 2021-01-27
Authors: Min Hu; Natasha M Rogers; Jennifer Li; Geoff Y Zhang; Yuan Min Wang; Karli Shaw; Philip J O'Connell; Stephen I Alexander Journal: Front Immunol Date: 2021-08-26 Impact factor: 7.561
Authors: Maya M Lapp; Guang Lin; Alexander Komin; Leah Andrews; Mei Knudson; Lauren Mossman; Giorgio Raimondi; Julia C Arciero Journal: Transpl Int Date: 2022-04-11 Impact factor: 3.842